The adoptive transfer of cultured T cells for patients with metastatic melanoma

Clinics in Dermatology

Volumn 31, Issue 2, 2013, Pages 209-219

  Yang, James C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GLYCOPROTEIN GP 100; INTERLEUKIN 2; MELAN A; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE T CELL TRANSFER; ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; DRUG MEGADOSE; HUMAN; LYMPHOCYTE TRANSFER; METASTATIC MELANOMA; NEUROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, NEOPLASM; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84874245002     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.019     Document Type: Article

References (44)

1. Klapper J.A., Downey S.G., Smith F.O., et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the Surgery Branch at the National Cancer Institute from 1986-2006. Cancer 2008, 113:293-301.
2. Smith F.O., Downey S.G., Klapper J.A., et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008, 14:5610-5618.
3. Rosenberg S.A., Yang J.C., White D.E., Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998, 228:307-319.
4. Prieto P.A., Yang J.C., Sherry R.M., et al. CTLA-4 Blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012, 18:2039-2047.
5. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
6. Robbins P.F., El-Gamil M., Li Y.F., Zeng G., Dudley M., Rosenberg S.A. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol 2002, 169:6036-6047.
7. Kawakami Y., Nishimura M.I., Restifo N.P., et al. T-cell recognition of human melanoma antigens. J Immunother Emphasis Tumor Immunol 1993, 14:88-93.
8. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
9. Yron I., Wood T.A., Spiess P.J., Rosenberg S.A. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980, 125:238-245.
10. Muul L.M., Spiess P.J., Director E.P., Rosenberg S.A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987, 138:989-995.
11. Topalian S.L., Muul L.M., Solomon D., Rosenberg S.A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987, 102:127-141.
12. Rosenberg S.A., Packard B.S., Aebersold P.M., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988, 319:1676-1680.
13. Rosenberg S.A., Yannelli J.R., Yang J.C., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86:1159-1166.
14. Kawakami Y., Robbins P.F., Rosenberg S.A. Human melanoma antigens recognized by T lymphocytes. Keio J Med 1996, 45:100-108.
15. Gnjatic S., Atanackovic D., Jager E., et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 2003, 100:8862-8867.
16. Robbins P.F., El-Gamil M., Li Y.F., et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996, 183:1185-1192.
17. Overwijk W.W., Theoret M.R., Finkelstein S.E., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 98:569-580.
18. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
19. Antony P.A., Piccirillo C.A., Akpinarli A., et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cell. J Immunol 2005, 174:2591-2601.
20. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005, 202:907-912.
21. Paulos C.M., Wrzesinski C., Kaiser A., et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007, 117:2197-2204.
22. Rosenberg S.A., Yang J.C., Sherry R.M., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
23. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23:2346-2357.
24. Hong J.J., Rosenberg S.A., Dudley M.E., et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010, 16:4892-4898.
25. Besser M.J., Shapira-Frommer R., Treves A.J., et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010, 16:2646-2655.
26. Chen Y.T., Scanlan M.J., Sahin U., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997, 94:1914-1918.
27. Hunder N.N., Wallen H., Cao J., et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008, 358:2698-2703.
28. Chapuis A.G., Thompson J.A., Margolin K.A., et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012, 109:4592-4597.
29. Dudley M.E., Wunderlich J., Nishimura M.I., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001, 24:363-373.
30. Powell D.J., Dudley M.E., Hogan K.A., Wunderlich J.R., Rosenberg S.A. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006, 177:6527-6539.
31. Matsushita H., Vesely M.D., Koboldt D.C., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
32. Morgan R.A., Dudley M.E., Yu Y.Y., et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003, 171:3287-3295.
33. Johnson L.A., Morgan R.A., Dudley M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
34. Robbins P.F., Morgan R.A., Feldman S.A., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924.
35. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
36. Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
37. Gattinoni L., Klebanoff C.A., Palmer D.C., et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005, 115:1616-1626.
38. Gattinoni L., Zhong X.S., Palmer D.C., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 2009, 15:808-813.
39. Klebanoff C.A., Finkelstein S.E., Surman D.R., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004, 101:1969-1974.
40. Kerkar S.P., Muranski P., Kaiser A., et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010, 70:6725-6734.
41. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993, 90:720-724.
42. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
43. Burns W.R., Zhao Y., Frankel T.L., et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res 2010, 70:3027-3033.
44. Robbins P.F., Dudley M.E., Wunderlich J., et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004, 173:7125-7130.